Weight Loss Drugs Chart

News

Novo Nordisk, Weight-Loss Drug

Novo Nordisk's weight loss challenge in five charts

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market capitalization since mid last year as competition from U.S. rival Eli Lilly and Co (LLY.N) and copycat rivals has hardened.

The Wall Street Journal on MSN · 11h

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.

Hosted on MSN · 22h

Novo Nordisk expands lawsuits against weight-loss drug compounders

(Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs,

1mon

Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

WLWT1mon

Major insurance changes are coming for weight loss drugs - WLWT

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...

KOAT Albuquerque1mon

Major insurance changes are coming for weight loss drugs

WLKY1mon

Major insurance changes are coming for weight loss drugs - WLKY

Results that may be inaccessible to you are currently showing.

Hide inaccessible results